Novel gonadotropin‐releasing hormone antagonists with substitutions at position 5

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biopolymers

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/bip.20195PMID 15614806
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.

  2001cited by this paper
• GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.

  2001cited by this paper
• Applications for GnRH antagonists.

  2001cited by this paper
• Betidamino acid scan of the GnRH antagonist acyline.

  1997cited by this paper
• Future trends in infertility treatment: challenges ahead.

  1997cited by this paper
• Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis.

  1996cited by this paper
• GnRH analogues : the state of the art 2001 : a summary of the 6th International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 2001

  1996cited by this paper
• Gonadotropin-releasing hormone antagonists: novel members of the azaline B family.

  1995cited by this paper
• Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.

  1993cited by this paper
• Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6.

  1992cited by this paper
• Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.

  1991cited by this paper
• Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N omega-cyanoguanidino moieties.

  1991cited by this paper
• GnRH agonists and antagonists. Current clinical status.

  1988cited by this paper
• Antide and related antagonists of luteinizing hormone release with long action and oral activity.

  1988cited by this paper
• Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective.

  1986cited by this paper
• New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro.

  1986cited by this paper
• Solid-phase peptide synthesis.

  1977cited by this paper
• Luteinizing hormone-releasing hormone. Antiovulatory activity of analogs substituted in positions 2 and 6.

  1975cited by this paper
• Synthetic luteinizing hormone-releasing factor analogs. Series of short-chain amide LRF homologs converging to the amino terminus.

  1973cited by this paper
• Synthetic Polypeptide Antagonists of the Hypothalamic Luteinizing Hormone Releasing Factor

  1972cited by this paper
• Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence.

  1971cited by this paper
• Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides.

  1970cited by this paper

• Mathematical Analysis of Osteoporotic Progression Induced by Androgen Deprivation Therapy (ADT)

  2026cites this paper
• Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection.

  2019cites this paper
• Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix. Part 1.

  2019cites this paper
• Histidine(7.36(305)) in the conserved peptide receptor activation domain of the gonadotropin releasing hormone receptor couples peptide binding and receptor activation.

  2015cites this paper
• Innovative Oral Treatments of Uterine Leiomyoma

  2012cites this paper
• Medical Treatment of Uterine Leiomyoma

  2012cites this paper
• Fibroids: a silent health problem affecting women in Trinidad and Tobago

  2012cites this paper
• Complications of Uterine Fibroids and Their Management

  2012cites this paper
• Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.

  2009cites this paper
• Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases

  2008cites this paper
• In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats.

  2006cites this paper
• Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.

  2006cites this paper
• Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.

  2005cites this paper